Loading organizations...
CERITD is a clinical research center dedicated to advancing diabetes treatment by integrating research and direct patient care. The organization develops innovative solutions for intensifying diabetes therapy. Its approach involves applying advanced tools like insulin pump protocols, real-world data collection via sensors, and adapted physical activity programs, aiming to improve the daily management of this chronic condition for patients.
Founded in 2006, CERITD emerged from the vision of diabetologist Guillaume Charpentier, who serves as its president. Charpentier initiated the medical research central to the center's mission, driven by the insight that a combined research and care methodology significantly enhances treatment outcomes. This focus on practical solutions reflects a deep understanding of daily challenges faced by individuals managing diabetes.
The center serves individuals living with diabetes, providing advanced therapeutic options and support to mitigate complications. CERITD's overarching mission is to continually research, develop, and disseminate innovative solutions that empower patients. By fostering continuous improvement in diabetes care, the organization ultimately strives to offer greater autonomy and a higher quality of life for those affected by the disease.
CERITD has 1 tracked investment across 1 company. The latest tracked deal is $74.8M Series C in Diabeloop in June 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 2, 2022 | Diabeloop | $74.8M Series C | Valery Huot | Agir A Dom., Cemag Invest, Crédit Agricole, Innovacom, Kreaxi, Odyss Venture, Promontoires, Supernova Invest, Hikaru Samejima, UI Investissement |